NCT07495631 2026-03-27
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Not yet recruiting
Clinical Trials
12 trialsNCT07372365 2026-01-28
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07199855 2025-09-30
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
Zhejiang University
Phase 2 Active not recruiting
NCT05827549 2025-06-06
ReCALL
Asan Medical Center
Phase 2 Recruiting
NCT06503263 2024-09-19
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Navy General Hospital, Beijing
Phase 2 Recruiting
NCT06341556 2024-09-04
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Fudan University
Phase 2 Recruiting
NCT02396043 2023-06-18
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Sun Yat-sen University
Phase 2 Unknown
NCT02063685 2022-06-21
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT03847727 2020-01-18
Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia
Pirogov Russian National Research Medical University
Unknown
NCT02858258 2017-12-19
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
European Mantle Cell Lymphoma Network
Phase 3 Recruiting
NCT02296398 2016-03-11
Long-term Use of Romidepsin in Patients With CTCL
Northwestern University
Completed
NCT01665001 2012-08-17
Personalized Therapy of Precursor Lymphoid Neoplasms
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Phase 2 Unknown